{"nctId":"NCT03734991","briefTitle":"Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)","startDateStruct":{"date":"2019-01-04","type":"ACTUAL"},"conditions":["Candida Vulvovaginitis"],"count":376,"armGroups":[{"label":"Ibrexafungerp (SCY-078)","type":"EXPERIMENTAL","interventionNames":["Drug: Ibrexafungerp"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Ibrexafungerp","otherNames":["SCY-078"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nSubject is a postmenarchal female subject 12 years and older\n\nSubject has a diagnosis of symptomatic AVVC at baseline including a positive microscopic examination with 10% KOH in a vaginal sample revealing yeast forms (hyphae/pseudohyphae) or budding yeasts, and vaginal pH (â‰¤4.5)\n\nExclusion Criteria:\n\nSubject has any vaginal condition other than AVVC that may interfere with the diagnosis or evaluation of response to therapy, such as suspected or confirmed concurrent causes of vulvovaginitis and/or cervicitis (mixed infection)\n\nNeed for systemic and/or topical (vaginal) antifungal treatment, including prescription or over-the-counter products during the study and treatment for VVC 28 days prior to randomization\n\nSubject is actively menstruating at the time of the Baseline visit.\n\nSubject has uncontrolled diabetes mellitus.\n\nSubject has a vaginal sample with pH \\>4.5.\n\nSubject has a history of or an active cervical/vaginal cancer.","healthyVolunteers":false,"sex":"FEMALE","genderBased":true,"minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Cure (Complete Resolution of Signs and Symptoms)","description":"measured by the percentage of subjects with clinical cure (complete resolution of signs and symptoms) at the test-of-cure (TOC) visit","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"28","spread":null}]},{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]}]},{"type":"SECONDARY","title":"Mycological Eradication (Negative Culture for Growth of Yeast)","description":"percentage of subjects with mycological eradication (negative culture for growth of Candida species) at the TOC visit","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"19","spread":null}]},{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Cure and Mycological Eradication (Responder Outcome)","description":"percentage of subjects with clinical cure and mycological eradication (responder outcome) at the TOC visit","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"12","spread":null}]},{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Clinical Response at Follow-Up","description":"percentage of subjects with complete resolution of signs and symptoms at the Follow-up (FU) visit","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"44","spread":null}]},{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Treatment-Emergent Adverse Events (Safety Set)","description":"Number of subjects with treatment related adverse events","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"21","spread":null}]},{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"103","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":247},"commonTop":["Diarrhoea","Nausea","Headache","Bacterial vaginosis","Abdominal pain"]}}}